Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | GSK3B | P49841 | 2/20 | 0.39 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.39 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.39 |
| ▸ | CYP21A2 | P08686 | 1/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.38 |
| ▸ | CDC7 | O00311 | 1/20 | 0.38 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.38 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.38 |
| ▸ | PIM1 | P11309 | 1/20 | 0.38 |
| ▸ | CDK2 | P24941 | 1/20 | 0.38 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.38 |
| ▸ | DAO | P14920 | 2/20 | 0.38 |
| ▸ | F10 | P00742 | 1/20 | 0.37 |
| ▸ | KIT | P10721 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6304944 | 0.89 | MAPK14 (0.43) | MAPK14KMT2AATML3MBTL1GSK3B | |
| SCHEMBL6305323 | 0.84 | MAPK14 (0.53) | MAPK14GSK3BROCK2MAP4K4CLK4 | |
| SCHEMBL27736020 | 0.73 | TAAR1 (0.57) | GSK3BCYP17A1CYP11B1CYP21A2TAAR1 | |
| SCHEMBL6304396 | 0.70 | CHEK1 (0.52) | CYP17A1CYP11B1CYP21A2CDK2 | |
| SCHEMBL6304393 | 0.70 | CHEK1 (0.52) | CYP17A1CYP11B1CYP21A2CDK2 | |
| SCHEMBL6304628 | 0.69 | CYP11B1 (0.44) | KMT2AATML3MBTL1GSK3BCYP17A1 | |
| SCHEMBL6302515 | 0.69 | KMT2A (0.43) | MAPK14KMT2AGSK3BCDC7ROCK2 | |
| SCHEMBL6302427 | 0.69 | BRD4 (0.42) | MAPK14CDC7ROCK2CDK2ROCK1 | |
| SCHEMBL5307626 | 0.69 | PIK3R1 (0.43) | ATMCLK4DAO | |
| SCHEMBL14519428 | 0.68 | NOTUM (0.43) | MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1019394-A1 | PYRAZOLE DERIVATIVES AS p38 KINASE INHIBITORS | G.D. Searle & Co. (US) | 2000-07-19 | — | — | EP | claimed |
| US-6087381-A | AN ENZYME INHIBITOR FOR INHIBITING PHOSPHORYLATION MEDIATE THE PRODUCTION OF INFLAMMATORY CYTOKINES, TUMOR NECROSIS FACTOR; TREATING INFLAMMATION, ARTHRITIS, A TNF MEDICATED DISORDER | G. D. SEARLE & COMPANY (US) | 2000-07-11 | — | — | US | claimed |
| WO-1998052941-A1 | PYRAZOLE DERIVATIVES AS p38 KINASE INHIBITORS | G.D. SEARLE AND CO. (US) | 1998-11-26 | — | — | WO | claimed |
| US-6852740-B2 | Pyrazole derivatives as p38 kinase inhibitors | G. D. SEARLE & CO. (US) | 2005-02-08 | — | — | US | disclosed |
| US-20030144529-A1 | Pyrazole derivatives as p38 kinase inhibitors | PHARMACIA CORPORATION | 2003-07-31 | — | — | US | disclosed |
| US-6503930-B1 | Treating cytokine-mediated diseases, such as inflammation | G.D. SEARLE & COMPANY | 2003-01-07 | — | — | US | disclosed |
| EP-1019394-A1 | PYRAZOLE DERIVATIVES AS p38 KINASE INHIBITORS | G.D. Searle & Co. (US) | 2000-07-19 | — | — | EP | disclosed |
| US-6087381-A | AN ENZYME INHIBITOR FOR INHIBITING PHOSPHORYLATION MEDIATE THE PRODUCTION OF INFLAMMATORY CYTOKINES, TUMOR NECROSIS FACTOR; TREATING INFLAMMATION, ARTHRITIS, A TNF MEDICATED DISORDER | G. D. SEARLE & COMPANY (US) | 2000-07-11 | — | — | US | disclosed |
| WO-1998052941-A1 | PYRAZOLE DERIVATIVES AS p38 KINASE INHIBITORS | G.D. SEARLE AND CO. (US) | 1998-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144529-A1 | Pyrazole derivatives as p38 kinase inhibitors | MAPK1, MAPK3, MAP3K1 | MAPK14 26/4885KMT2A 3185/4885ATM 531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.